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Abstract In this study we have analyzed the role of the platelet- 
endothelial cell adhesion molecule-1 (PECAMI) in vascular bar- 
rier function. PECAMI is an immunoglobulin gene superfamily 
member expressed by endothelial cells at the cell boundaries. 
Macromolecule permeability assays performed on cell monolay- 
ers that express native or transfected PECAM1, indicated that 
the molecule participates in the establishment and maintenance 
of vascular barrier function in vitro. This hypothesis was con- 
firmed by the finding that in vivo injection of the specific monoclo- 
nal antibody directed against the murine vascular PECAMI led 
to a detectable leakage of hepatic and renal blood vessels. 
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1. Introduction 
Vascular endothelium forms an active boundary between the 
bloodstream and the underlying tissues, retaining blood com- 
ponents within the intravascular space [1,2]. The integrity of the 
endothelial monolayer is a pre-requisite to dynamically control 
vascular permeability and is dependent on the presence of spe- 
cialized junctions located between adjacent endothelial cells 
(EC) as well as on the anchoring of the basal side to subendo- 
thelial extracellular matrix [1,2]. 
A number of integral membrane molecules are implicated in 
the organization and maintenance of EC intercellular junctions: 
among them, cadherins [3,4] and integrins, mainly ~5fll and 
c~2fll [5]. The platelet-endothelial cell adhesion molecule-1 
(PECAM1), also known as CD31, has been recently described 
as an additional molecule localized at the intercellular junctions 
and responsible for the formation of cell monolayers in vascular 
endothelium [6-9]. 
We have been interested in the role of PECAM1 as a cell 
adhesion molecule involved in lymphocyte activation and 
transendothelial migration [10,11]. In this study we demon- 
strate that both endogenously and ectopically expressed vascu- 
lar PECAM1 is involved in maintaining EC monolayer integ- 
rity in vitro. We also provide evidence for a role of PECAM 1 
in the maintenance of vascular barrier functions in vivo. 
2. Methods 
2.1. Monoclonal antibodies (mAbs) 
In the present study the following mAbs were used: the anti- 
PECAM1 mAbs M89D3 (formerly LAKI: 10, 12; see also Fig. 3); the 
anti-LFA3 (AICD58) obtained from Immunotech (Luminy, Marseille, 
France); the anti-murine PECAM 1 (clone MEC 13.3, IgG2a), the anti- 
murine ICAM1 (clone 3E2, IgG) and the anti-L3T4 (clone RM4-5, 
IgG2a) mAbs from Pharmingen (San Diego, CA). All the purified 
antibodies were extensively dialyzed and used at concentrations from 
10 to 0.1 pg/ml in functional in vitro assays and a dose of 50 pg was 
used in in vivo studies. 
2.2. Endothelial cell cultures and treatments 
Human endothelial cells were isolated from umbilical vein (HUVEC: 
from now on EC) and cultured as described [13]. Cells were used within 
four passages. Exposure of EC (or PECAM 1 transfectants; see below) 
to either intact orpepsin digested monoclonal ntibodies (F(ab')2, pre- 
pared according to Parham, ref[14]) was performed for 30 min at room 
temperature (to avoid any possible damage of the endothelial mono- 
layer due to low temperature); cells were then washed three times and
used. The ECV304 cell line [15] obtained from J.S. Pober (Yale Univer- 
sity, Yale), was maintained in culture with DMEM containing 10% 
FCS. 
2.3. PECAM1 transfectants 
Lines D12P and P-ECV were made from NIH/3T3 murine fibro- 
blasts or ECV304 human EC, respectively, with PECAMI and neomy- 
cin resistance on the same plasmid. PECAM1 was subcloned into 
pcDNAI/Neo (Invitrogen, San Diego, CA) at the Xhol (5') NsiI (3') 
sites from the original pGEM7 vector (PECAM-1/pGEM7 (ref. [7]) was 
kindly provided by Dr. Peter Newmann, Blood Center of South-eastern 
Wisconsin, Milwaukee). Transfection was performed by calcium phos- 
phate-DNA co-precipitation. Stable transfectants were selected by ad- 
dition, after 48 h, of the neomycin analogue G418 (0.8 mg/ml). Neomy- 
cin resistant colonies were picked 10 days later, expanded and tested 
for PECAM expression by immunofluorescence using mAbs 5.6E (Im- 
munotech) and M89D3. Mock transfected ECV304 and NIH/3T3 cells 
were used as negative controls. 
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2.4. Permeability assay 
The Transwell cell culture chambers (polycarbonate filters, 0.4 pm 
pore size, Costar) were used as described [16]. Briefly, 5 x 104 EC, 
ECV304, D12P, P-ECV or mock transfectants were seeded onto the 
filters and grown to confluence. Some samples were exposed to various 
dilutions of the AICD58 or the M89D3 mAb (from 10 to 1 /.tg/ml). 
[~25I]Albumin (1mCi/ml, NEN, Boston, MA) was added to the upper 
chamber; cold albumin (1.5 mg/ml) was added to the culture medium 
to minimize transcytosis (this concentration being saturating according 
to Simionescu and Simionescu (ref. [1]). Samples were taken from the 
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lower chamber 1 h after addition of [125I]albumin a d the radioactivity 
was measured in a ),-counter (Packard, Sterling, VA). Results are the 
mean + S.D. from I0 independent experiments with different EC lines 
and are expressed as albumin flux (pmol.cm 2.s-~) according to 
Fick's law (Js = ACslSzlt). 
2.5. Surface iodination and immunoprecipitation 
Surface PECAM1- ECV304 endothelial cell line, PECAM1 ÷ D12P 
clone, PECAM 1 ÷ transfected P-ECV cell line or mock transfected NIH/ 
3T3 murine fibroblasts (E5) were iodinated (IZSIodine, 0.5 mCi/107 cells; 
NEN DuPont) using a lactoperoxidase catalyzed reaction [10]. Cells 
were then lysed in 1% NP-40 lysis buffer containing 10/~M pepstatin, 
10/zM aprotin, 10/IM leupeptin, 10/IM antipain, 10/~M phenylmeth- 
ylsulphonyl fluoride (Sigma). For immunoprecipitation, mAbs were 
coupled to protein-G sepharose; then 100/A (100 ¢tg protein) of pre- 
cleared cell lysate were incubated with the pellet beads for 12 h at 4°C 
under rotation. Beads were washed twice and samples eluted at 50°C 
for 20 min. After separation by SDS electrophoresis (12.5% gel) the gel 
was dried and autoradiography performed at -70°C with appropriate 
films (NEN DuPont). 
2.6. In vivo experiments 
Balb/C mice (n = 6; Charles Rivers Italia, Como, Italy) were anesthe- 
tized with ether. The liver was perfused with 4% albumin in Evans blue 
through the inferior vena cava and the perfusate drawn from the portal 
vein according to Branster and Morton [17]. The right kidney was 
perfused through the renal artery as previously described [18]. Fifty 
micrograms of the anti-murine PECAM 1, or the anti-murine ICAMI 
or the anti-L3T4 mAbs were injected into the vena cava or the renal 
artery 15 min before the beginning of dye perfusion. Perfusion with 
saline alone or Evans blue alone was also performed. Both liver and 
kidney were then washed with saline, immediately removed and homog- 
enized with buffered phosphate solution, pH 7.4. Samples were centri- 
fuged and the supernatants recovered and treated with 10% deoxycolic 
acid (DOC, sodium salt monohydrate, Sigma) in saline. Dye presence 
was evaluated by spectrofotometric analysis (Pye Unicam, SP6-550, 
Cambridge, UK) at 540 nm wavelength. 
3. Results 
3.1. Contribution of  PECAM1 to the maintenance of  vascular 
barrier Junction 
Confluent monolayers of EC were analyzed for their ability 
to prevent he trans-endothelial flux of a radioactive macromol- 
ecule, [~25I]albumin, in the presence or absence of the blocking 
anti-PECAM1 mAb M89D3. Fig. l A shows that ['25I]albumin 
flux through EC monolayers was enhanced by preincubation 
with the specific anti-PECAM1 mAb; albumin flux increased 
from 0.2 + 0.05 pmol'cm-2"s ~ when EC were exposed to cul- 
ture medium alone, to 1.2 + 0.08 pmol.cm-2.s -~ when they 
were treated with the M89D3 mAb. The effect of the anti- 
PECAM mAb was also detectable using the F(ab')2 fragment 
and showed a clear dose-dependence (Fig. 1A). Similar effects 
were observed using the Fab' of the M89D3 mAb (not shown). 
A mAb directed against LFA3, a molecule whose EC surface 
density is comparable to PECAM 1 (not shown), did not affect 
albumin flux (Fig. 1A). A control anti-human ICAM1, whose 
surface expression was lower than that of LFA3, did not exert 
any detectable ffect (not shown); conversely, co-incubation of 
EC with both M89D3 mAb and an anti-E-cadherin or an anti- 
N cadherin mAb increased the permeability up to 1.7 + 0.05 
pmol. cm -2. s ' (not shown). Baseline transit of albumin in this 
assay (0.2_+0.05 pmol'cm-2"s ~) was consistently low and 
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Fig. 1. [t25I]Albumin transit through endothelial and non-endothelial cellmonolayers: contribution of PECAMI. All the values are referred to 
measurements performed 1 h after albumin addition; results are expressed as albumin flux, pmol.cm -2.s -t. (A) Effect of undigested or F(ab')2 
fragment of the anti-PECAM M89D3 mAb. The anti-LFA3 mAb AICD58 was used as a control. (B) [J25I]Albumin transit hrough human PECAM 1 ÷ 
transfectant (clone D12P and P-ECV) monolayers compared to mock transfected NIH/3T3 cells (clone E5) and the PECAM1- ECV304 human 
endothelial cell line. Effect of the F(ab')2 fragment of anti-PECAM1 M89D3 mAb (5/tg/ml) on albumin flux, through clone D12P, clone P-ECV, 
ECV304 cell line or mock transfected E5. The anti-LFA3 mAb AICD58 was used as a control. Inset: surface labelling and immunoprecipitation of 
PECAM1 from E5 clone (mock), D12P clone, ECV304 cell line and P-ECV clone. 
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Table 1 
Perturbation of endothelial barrier function in vivo by injection f
anti-PECAM 1 antibodies 
Treatments ~ Vascular leakage OD (540 nm) 2 
Liver Kidney 
Saline 324 + 54 310 + 50 
Anti-PECAMI mAb 1176 + 103 1062 + 53 
Anti ICAM1 mAb 450 + 34 378 + 28 
Anti L3T4 mAb 499 + 13 322 + 9 
Anesthetized mice (n = 6) were injected (in the vena cava or the renal 
artery) with either the anti-murine PECAM1 mAb(50/tg) or the anti- 
ICAM 1 mAb (50/.tg) or the anti-L3T4 mAb (50 ¢tg) followed (alter 15 
min) by organ perfusion with Evans blue and washing with saline. 
Control is represented by dye-perfused, saline-washed organs. Maxi- 
mum dye retention (dye perfusion without washing) yieldan O.D. of 
1056 + 9. 
2 Liver and kidney were homogenized, centrifuged and th  supernatants 
treated with 10% DOC. Samples were then ru on a spectrofotometer 
at 540 nm wavelength. Results are the mean + S.D. from 6 independent 
experiments. 
comparable to that reported in the literature (about 0.2 pmol/h; 
ref[19]). Similar esults were also obtained using microvascular 
endothelia isolated from human dermal vessels (not shown). 
3.2. Ectopically expressed PECAM1 contributes to monolayer 
integrity 
To confirm the function of PECAM 1 in the maintenance of 
vascular barrier function, we generated cell clones stably ex- 
pressing human PECAM 1 from both murine fibroblasts (clone 
D12P) and from the human endothelial cell line ECV304 (clone 
P-ECV). Permeability to radiolabeled albumin was evaluated 
in D12P cells and compared to mock transfected NIH/3T3 
murine fibroblasts or to the surface PECAM1- human endo- 
thelial cell line ECV304 and the transfected clone P-ECV ob- 
tained from the ECV304 cell line (Fig. 1B). PECAMI ÷ stable 
transfectants (D12P and P-ECV) expressed considerable 
amounts of the molecule, a large fraction of which reaches the 
cell surface, as shown by immunoprecipitation after surface 
iodination (Fig. 1B, inset). Fig. 1B shows that albumin flux 
through PECAM1 transfected D12P and P-ECV was approxi- 
mately 60% and 50% lower, respectively, than that observed in 
mock transfected NIH/3T3 or ECV304 cells. Moreover, the 
F(ab')2 fragment of the anti-PECAM1 mAb M89D3 increased 
the permeability of PECAM 1 transfectants; bycontrast, prein- 
cubation with the M89D3 mAb did not affect the transit of 
iodinated albumin in mock transfectants or in ECV304 cells 
(Fig. 1B), that do not express PECAMI at the cell surface (Fig. 
I B, inset). An anti-LFA3 mAb, used as a negative control, 
did not exert any effects on all the clones and cell lines tested 
(Fig. 1B). 
3.3. PECAM1 contribution to the maintenance of vascular 
barrier function is effective in vivo 
As PECAM1 contribution to endothelial integrity has been 
shown to be mainly effective during the formation of endothe- 
lial cell monolayers in vitro [9, 20], we addressed the question 
of whether a perturbation ofvascular endothelial barrier func- 
tion could be achieved in vivo by injection of the specific anti- 
murine PECAMI mAb in mice. Leakage of Evans blue/albu- 
min from liver and kidney vessels was evaluated by dye perfu- 
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sion, according to Westergen et al. [21]. Injection of the anti- 
murine PECAM 1 mAb (50/2g), followed by dye perfusion and 
washing with saline, caused an increase of dye retention by both 
liver and kidney, compared to saline or anti-murine ICAMI or 
anti-L3T4 mAbs (an anti-murine LFA3 mAb was not availa- 
ble) (Table 1), possibly due to an increase in vascular permea- 
bility. Evans blue/albumin extravasation was also detected by 
immunoreactivity with an anti-albumin antibody (not shown). 
Similar results were obtained by the use of a vessel permeabil- 
izing factor (tumor necrosis factor ~) (not shown). 
4. Discussion 
In the present report we demonstrate that PECAM1, 
which has been described as a junctional structure xpressed 
on EC monolayers [6 9], has a relevant function in the main- 
tenance of vascular endothelium integrity both in vitro and 
in vivo. 
In our experiments PECAM1 proved to be involved in endo- 
thelial barrier function. Indeed, transfection of PECAM1 
cDNA into NIH/3T3 murine fibroblasts or into the ECV304 
surface PECAM l- endothelial cell line, and subsequent expres- 
sion of the protein at the cell surface, decreased the baseline 
permeability to macromolecules of transfectant monolayers 
compared to wild type or mock transfected cells. In all cases, 
the specific monoclonal ntibody could selectively increase the 
albumin flux through the PECAM 1 ÷ monolayers. The antibody 
effect was unlikely to be due to a signal delivered via PECAM1 
clustering, as it was also detectable with the F(ab') 2 (see section 
3) and Fab' (not shown) fragments. Moreover, we could not 
observe a 'capping' of the molecule by immunofluorescence or 
major changes in morphology after EC incubation with the 
antibody (not shown). Thus, we favour the hypothesis of an 
interference of the antibody with homodimeric PECAMI-  
PECAM1 interactions in EC contacts. 
These results indicate that PECAM1 contributes to the 
strengthening of cell~cell contacts whereby vascular endothe- 
lium can maintain its integrity and exert its functions. It has to 
be noted that D12P and P-ECV lines originated from two 
different cell types: fibroblasts and endothelial cells, the former 
reported to lack adherens or tight junctions, the latter equipped 
with other junctional molecules such as cadherins or integrins 
[14]. This might explain the more pronounced effect of the 
anti-PECAM1 antibody in the transfected fibroblasts, where 
the molecule plays indeed a mechanistic role in the strengthen- 
ing of the intercellular contacts, as judged by the decreased 
levels of baseline permeability resulting from PECAM 1 expres- 
sion. Conversely, the other junctional molecules might provide 
P-ECV with additional tools for the maintenance of barrier 
integrity: this is also supported by the finding that co-incuba- 
tion of EC with mAbs directed against known endothelial cad- 
herins leads to an additional increase in albumin flux. 
So far, it has been claimed that PECAM1 contribution to 
endothelial integrity is mainly confined to the formation of the 
endothelial cell monolayers invitro, whereas it is not primarily 
involved in the perturbation of already established monolayers 
[9,20]. Thus, we addressed the question of whether a perturba- 
tion of vascular barrier function could be achieved in vivo by 
injection of the specific anti-PECAM1 antibody in mice. At 
variance with the above mentioned reports, all referred to in 
vitro experiments, we found that vascular endothelium be- 
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comes highly permeabile as a consequence of anti-PECAM1 
mAb infusion, thus supporting the hypothesis that PECAM1- 
mediated cell-cell contacts are operating in vivo and contribute 
not only to the formation but also to the maintenance of endo- 
thelium integrity. 
In conclusion, PECAM1 appears to be one of the molecules 
responsible for the endothelial continuity required for the 
maintenance of vascular barrier function: thus, we would imply 
that an abnormal or altered localization of PECAM 1 along the 
endothelial cell membrane might contribute to the pathogenesis 
of both acute and chronic diseases involving vascular endothe- 
lium. 
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